<DOC>
	<DOCNO>NCT02162693</DOCNO>
	<brief_summary>Current medication treatment KOA aim relieve inflammation pain , little delay reverse disease progression medication obvious side effect . When conservative treatment useless patient joint deformity joint disfunction , patient may require surgery . Although surgery joint relieve pain temporarily , long-term effect ( 10 year ) hard achieve .</brief_summary>
	<brief_title>Clinical Trial Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells ( MPCs ) Therapy Knee Osteoarthritis</brief_title>
	<detailed_description>Human adipose-derived mesenchymal progenitor cell ( haMPCs ) obtain series procedure : firstly , fresh adipose tissue digest collagenase , filter , centrifuge discard mature adipose cell obtain adipose tissue-derived nuclear cell also call stromal vascular fraction cell ( SVFs ) . In end , haMPCs prepare purified andamplified P2-P5 . When induced specific factor , haMPCs potential multilineage differentiation towards bone , cartilage fat tissue vivo vitro . The haMPCs secrete number soluble mediator stimulate proliferation endogenous progenitor cell , act nutrient , immunosuppressive , anti-inflammatory , prevent fibrosis promote angiogenesis . The cytokine secrete haMPCs play synergic role restore dynamic balance synthesis decompositon cartilage tissue , finally repair impaired cartilage .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . The subject 1870 year age , regardless gender 2 . The subject KellgrenLawrence grading , determine American College Rheumatology ( ACR ) criteria osteoarthritis knee , grade 4 3 . The subject subject 's legally acceptable representative must willing participate trial , receive cell therapy provide sign date informed consent form 1 . The subject allergic history allergic constitution 2 . The subject uncontrolled hardtocontrol disease heart , liver , kidney lung 3 . The subject uncontrolled hardtocontrol disease cardiovascular endocrine system 4 . The subject severe infectious disease malignant tumour 5 . The subject coagulation disorder 6 . The subject BMI 30 7 . The subject use traditional Chinese medicine contain antiinflammatory agent 2 week precede trial 8 . The subject receive intraarticular injection 2 month precede trial 9 . The subject complication disease : systemic rheumatoid arthritis , Chondrocalcinosis articular， Hemochromatosis，inflammatory arthropathy，avascular necrosis femoral head，Paget 's disease，hemophilic arthropathy，infectional arthritis，Charcot 's disease，villonodular synovitis synovial chondromatosis 10 . The subject test positive : HIV , hepatitis virus , syphilis infectious disease 11 . The subject history alcoholism , drug abuse , mental illness 12 . The subject participate clinical trial 3 month prior trial 13 . The subject pregnant , lactate plan conceive within next 6 month 14 . The subject unsuitable adverse condition determine investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>